1093283-41-0

Basic information

• Product Name: 3'-azido-N₄-benzoyl-5'-O-(p-bromobenzoyl)-2',3'-dideoxycytidine
• Synonyms: 3'-azido-N₄-benzoyl-5'-O-(p-bromobenzoyl)-2',3'-dideoxycytidine
• CAS NO: 1093283-41-0
• Molecular Weight: 539.345
• Mol File: 1093283-41-0.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 3'-azido-N₄-benzoyl-5'-O-(p-bromobenzoyl)-2',3'-dideoxycytidine(CAS DataBase Reference)
• NIST Chemistry Reference: 3'-azido-N₄-benzoyl-5'-O-(p-bromobenzoyl)-2',3'-dideoxycytidine(1093283-41-0)
• EPA Substance Registry System: 3'-azido-N₄-benzoyl-5'-O-(p-bromobenzoyl)-2',3'-dideoxycytidine(1093283-41-0)

Safety Data

• Hazardous Substances Data: 1093283-41-0(Hazardous Substances Data)

Upstream product

• 1093283-40-9 C₂₃H₁₈BrN₃O₅ 
• 4836-13-9 N₄-benzoyl-2'-deoxycytidine 
• 951-77-9 2'-Deoxycytidine 
• 586-76-5 4-Bromobenzoic acid 

Downstream Products

• 124930-55-8 3’-azido N4-benzoyl 2’-deoxycytidine 

Relevant articles and documents

Towards Zwitterionic Oligonucleotides with Improved Properties: the NAA/LNA-Gapmer Approach

Oligonucleotides (ON) are promising therapeutic candidates, for instance by blocking endogenous mRNA (antisense mechanism). However, ON usually require structural modifications of the native nucleic acid backbone to ensure satisfying pharmacokinetic properties. One such strategy to design novel antisense oligonucleotides is to replace native phosphate diester units by positively charged artificial linkages, thus leading to (partially) zwitterionic backbone structures. Herein, we report a “gapmer” architecture comprised of one zwitterionic central segment (“gap”) containing nucleosyl amino acid (NAA) modifications and two outer segments of locked nucleic acid (LNA). This NAA/LNA-gapmer approach furnished a partially zwitterionic ON with optimised properties: i) the formation of stable ON-RNA duplexes with base-pairing fidelity and superior target selectivity at 37 °C; and ii) excellent stability in complex biological media. Overall, the NAA/LNA-gapmer approach is thus established as a strategy to design partially zwitterionic ON for the future development of novel antisense agents.